Taking ADCs beyond oncology
Merck looking beyond cancer in antibody-drug conjugate deal with Ambrx
Merck & Co. Inc. partnered with Ambrx Inc. because the pharma hopes to build upon the biotech's near-decade of experience in site-specific peptide modification to move antibody-drug conjugates beyond oncology.
Last month, Merck agreed to pay Ambrx $15 million up front and up to $288 million in milestones to use this technology to develop antibodies against an undisclosed number of pre-defined targets. The deal marks Ambrx's third antibody partnership in three years.
Merck cited Ambrx's experience in peptide modification - as well as its own history with the biotech company - as reasons behind its partnering choice.
Richard Murray, SVP of biologics at